Fertility and Sterility
Volume 91, Issue 3 , Pages 659-663, March 2009

Return to fertility following discontinuation of oral contraceptives

  • Kurt T. Barnhart, M.D., M.S.C.E.

      Affiliations

    • Corresponding Author InformationReprint requests: Kurt T. Barnhart, M.D., Hospital of the University of Pennsylvania, Department of Obstetrics and Gynecology, 3701 Market St., 8th floor, Philadelphia, PA19104 (TEL: 215-662-2951; FAX: 215-349-5512).
    • ,
  • Courtney A. Schreiber, M.D., M.P.H.

Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Received 6 March 2008; accepted 6 January 2009.

Objectives

To provide an overview of the studies that have evaluated the return to fertility following cessation of oral contraceptives (OCs), including recent evidence in women discontinuing extended-cycle and continuous-use regimens.

Design

Comprehensive review.

Patient(s)

None.

Intervention(s)

Relevant articles were identified through a PubMed literature search (1960–2007) and a cross-reference of published data.

Main Outcome Measure(s)

Time to fertility following contraceptive use.

Result(s)

Numerous studies have demonstrated some delay in the time to conception in previous users of OCs who discontinued use in order to conceive, but this impairment appears to be temporary and typically limited to the early months following cessation of OC use. Reported 12-month conception rates in former cyclic OC users range from 72%–94% and are similar to those observed in women discontinuing intrauterine devices (71%–92%), progestin-only contraceptives (70%–95%), condoms (91%), and natural family planning (92%). There is a limited amount of data on the time to conception in women stopping extended-cycle and continuous-use OCs, but the data suggest that subsequent return to fertility is generally comparable to that of cyclic OCs.

Conclusion(s)

A comprehensive survey of reported data indicates that the return of fertility in former OC users (both cyclic and extended/continuous regimens) in women who stop use in order to conceive is comparable to that observed with other contraceptive methods.

Key Words: Fertility, oral contraceptives, extended cycle, continuous use

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Wyeth Pharmaceuticals, Collegeville, PA. The authors were not compensated and retained full editorial control over the content of the manuscript.

 K.B. has served as a clinical trial investigator for Wyeth-Ayerst, Organon, Johnson & Johnson, Duramed, Xanodyne, Boehringer Ingelheim, Third Wave, Pfizer, and MGI Pharma; he has served as a consultant for Novo Nordisk and on the Speaker Bureau for Organon. C.A.S. has nothing to disclose.

PII: S0015-0282(09)00049-1

doi:10.1016/j.fertnstert.2009.01.003

Fertility and Sterility
Volume 91, Issue 3 , Pages 659-663, March 2009

Article Tools

* Image Usage & Resolution